COMPASS Pathways plc (CMPS) Stock

Healthcare · Medical Care Facilities · Member of Other US Stocks

COMPASS Pathways plc (CMPS) closed at USD 11.27 on 2026-10-14, a change of +72.1 % over the past year, with a market capitalization of USD 1.61B.

COMPASS Pathways plc recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

COMPASS Pathways plc key figures

Previous close

USD 11.27 (2026-10-14)

1-year change

+72.1 %

Market cap

USD 1.61B

Enterprise value

USD 1.23B

P/E ratio (trailing)

-2.96

P/E ratio (forward)

-8.11

EPS (trailing)

-3.92

EPS (forward)

-1.43

PEG ratio

n/a

Price to book

18.65

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.08

Employees

156

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About COMPASS Pathways plc

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for COMPASS Pathways plc and compare it with other stocks.